Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Thymmune Therapeutics General Information
The company is developing thymic cell therapies and has raised seed funding to push its therapy through preclinical studies. No clinical results are available yet as the company is still in early stages.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
THY-100
Pre-clinicalKey Partnerships
Thymmune Therapeutics Funding
No funding data available
To view Thymmune Therapeutics's complete valuation and funding history, request access »